类风湿Ⅰ号治疗类风湿关节炎的临床及实验研究
|
摘要
本研究包括三方面内容,①理论部分：整理古代有关“痹证”文献并总结分昕宋师提出的“伏邪晚发致痹”学术思想。②临床部分：系统观察类风湿I号治序活动期RA的临床疗效,并进行安全性评价。③实验部分：观察活动期RA血清中JAK-STAT蛋白与NEI网络因子的表达,并观察类风湿I号对相关蛋白及因子的影响,从而为进一步探讨类风湿I号的作用机理提供依据。
方法①理论部分：通过整理古代文献,挖掘宋师“伏邪晚发致痹”学术思想理论渊源。②临床部分：选择符合2009年ACR有关RA分类标准的活动期RA患者90例,随机分组,治疗组予类风湿I号联合雷公藤多甙片治疗,对照组予雷公藤多甙片治疗,观察周期为12周。观察两组患者ACR及DAS28变化,评价其临床疗效及安全性。主要观察指标包括：疼痛关节数、肿胀关节数、关节疼痛(VAS评分)、晨僵时间、双手握力及ESR、CRP、RF、CCP及血常规、肝功能等。③实验部分：选择活动期RA患者40例,将40例RA患者随机分为2组,分别予类风湿I号联合雷公藤多甙片和单纯雷公藤多甙片治疗,观察周期为12周,用ELISA法测定RA患者治疗前后血清中JAK1、STAT3、IL-6、IL-21、 SP及PRL的浓度,并与健康对照者20例比较,分析RA患者治疗前后血清中6指标的变化。
结果①理论部分：总结宋师提出“伏邪晚发致痹”学术思想理论渊源,宋师认为脾气亏虚、湿热痰瘀痹阻是活动期RA的核心病机,提出从复法大方治痹的治疗原则,自创类风湿I号并运用于临床。②临床部分：类风湿I号治疗活动期RA疗效明显,DAS28总有效率为93.33%；100%达ACR20,77.78%达ACR50,42.22%达ACR70。临床症状方面,类风湿I号不仅能明显改善晨僵时间、双手握力,减少关节疼痛数目和肿胀数目还能明显降低CRP、ESR、抗CCP抗体水平,而且安全性高,无明显毒副作用。③实验部分：活动期RA患者JAK1,STAT3, IL-6, IL-21, SP及PRL血清浓度水平显著高于健康对照组。治疗活动期RA12周后,RA对照组和治疗组6因子浓度均有不同程度的下调,且治疗组在IL,-6、JAK1、STAT3及SP下降更明显。
结论类风湿I号是宋师基于“伏邪晚发致痹”及“脾气亏虚、湿热痰瘀痹阻”是活动期RA的核心病机等学术思想所创的中药复方；类风湿I号能显著改善活动期RA的临床症状,降低炎症活动实验室指标,且不良反应小；类风湿关节炎活动期,JAK-STAT信号通路和神经内分泌免疫网络处于激活状态,类风湿I号可抑制JAK-STAT信号通路蛋白和NEI网络因子的表达。
Objective This subject include three parts.①Theoriest part,I learn formed form TCM classic theories and my tutor get the knowledge that as "hidden-pathogens causing rheumatism doctrine"②Clinical part, systematic evaluate and compare the therapeutic efficacy of Rheumatoid one in treating activated arthritis to evaluate the clinical effect and drug-using security.③Experiment research,we using the serum of RA patient,testing the level of JAK-STAT proteins and some factors of NEI network,then to observe the effect of Rheumatoid one to them,in order to provide the basis of the mechanism of this drug worked on arthritis.
Methods①Theoriest part, by collectting the TCM classic theories,we found the origin theory of the knowledge "hidden-pathogens causing rheumatism doctrine".②Clinic Part:By American College Rheumatology(ACR)standard classification of2009for diagnosis basis.Ninety patients of RA were randomly divided into two group.The treatment group treated with Rheumatoid one Combined With Tripterygium wilfordii while the control group only treated withTripterygium wilfordii. The treatment of12weeks was observed in the Patients with the difference of ACR and DAS28to evaluated its clinical efficacy.Main outcome measures:include tender joint count,swellon joints count,pain joint count,visual analogue scale test,time of morning stiffness(min),hand grip strength (mmHg) and ESR,CRP,RF,a-CCP, PLT,RBC,WBC,HGB,ALT,AST.③Experiment research:we choose forty patients whose disease at the activity time, then randomly divided the forty patients into two groups as the treatment group which treated with Rheumatoid one Combined With Tripterygium wilfordii while the control group only treated with Tripterygium wilfordii. Using ELIS A method for the determination of serum JAK1,STAT3,IL-6, IL-21,SP,PRL.The observe time is twelve weeks. Meanwhile, we choose twenty healthy people as controls,. observe the change of six indexes in the serum,and compare the after-treating indexes with the before-treating in activity RA.
Results①Theoriest part, We think that main pathology mechanism of RA in periods of activity is low-speel function, damp-heat and stasis-toxicant obstructing channels and flowing to limbs joints. We work form complex way and large amount of the medicine making the drug called Rheumatoid one.②Clinic Part:after treatment for3months, the treatment group got a better overall assessment, The total effective rate of DAS28is93.3%,all patients got ACR20,77.8%patients got ACR50and42.22%patients got ACR70.Signs and symptoms aspect:Rheumatoid one play a good role not only on relieve the pain and swelling, morning stiffness, grip strength, pain VAS score and patient overall health status and also show at blood indicators:ESR, CRP, RF and a-CCP have varying degrees of decline after treatment. Meanwhile Rheumatoid one have low adverse effects, no adverse effects of combination therapy superposition.③Experiment research:the serum of JAK1,STAT3,IL-6,IL-21,SP, PRL which owed by activity RA is higher than healthy ones.After treatment,both groups make these factors low in different extent,and the group with Rheumatoid one get more obvious low in IL-6,JAK1,STAT3and SP.
Conclusion Rheumatoid one is an origin theory based on my tearchers academic thought; It can significantly alleviate the clinical symptoms of patients, significantly reduce laboratory index,and have less adverse reaction;Being activity RA,the JAK-STAT load and NEI network is being actived, Rheumatoid one can partially inhibit the activation of JAK-STAT protein and NEI network factor.
方法①理论部分：通过整理古代文献,挖掘宋师“伏邪晚发致痹”学术思想理论渊源。②临床部分：选择符合2009年ACR有关RA分类标准的活动期RA患者90例,随机分组,治疗组予类风湿I号联合雷公藤多甙片治疗,对照组予雷公藤多甙片治疗,观察周期为12周。观察两组患者ACR及DAS28变化,评价其临床疗效及安全性。主要观察指标包括：疼痛关节数、肿胀关节数、关节疼痛(VAS评分)、晨僵时间、双手握力及ESR、CRP、RF、CCP及血常规、肝功能等。③实验部分：选择活动期RA患者40例,将40例RA患者随机分为2组,分别予类风湿I号联合雷公藤多甙片和单纯雷公藤多甙片治疗,观察周期为12周,用ELISA法测定RA患者治疗前后血清中JAK1、STAT3、IL-6、IL-21、 SP及PRL的浓度,并与健康对照者20例比较,分析RA患者治疗前后血清中6指标的变化。
结果①理论部分：总结宋师提出“伏邪晚发致痹”学术思想理论渊源,宋师认为脾气亏虚、湿热痰瘀痹阻是活动期RA的核心病机,提出从复法大方治痹的治疗原则,自创类风湿I号并运用于临床。②临床部分：类风湿I号治疗活动期RA疗效明显,DAS28总有效率为93.33%；100%达ACR20,77.78%达ACR50,42.22%达ACR70。临床症状方面,类风湿I号不仅能明显改善晨僵时间、双手握力,减少关节疼痛数目和肿胀数目还能明显降低CRP、ESR、抗CCP抗体水平,而且安全性高,无明显毒副作用。③实验部分：活动期RA患者JAK1,STAT3, IL-6, IL-21, SP及PRL血清浓度水平显著高于健康对照组。治疗活动期RA12周后,RA对照组和治疗组6因子浓度均有不同程度的下调,且治疗组在IL,-6、JAK1、STAT3及SP下降更明显。
结论类风湿I号是宋师基于“伏邪晚发致痹”及“脾气亏虚、湿热痰瘀痹阻”是活动期RA的核心病机等学术思想所创的中药复方；类风湿I号能显著改善活动期RA的临床症状,降低炎症活动实验室指标,且不良反应小；类风湿关节炎活动期,JAK-STAT信号通路和神经内分泌免疫网络处于激活状态,类风湿I号可抑制JAK-STAT信号通路蛋白和NEI网络因子的表达。
Objective This subject include three parts.①Theoriest part,I learn formed form TCM classic theories and my tutor get the knowledge that as "hidden-pathogens causing rheumatism doctrine"②Clinical part, systematic evaluate and compare the therapeutic efficacy of Rheumatoid one in treating activated arthritis to evaluate the clinical effect and drug-using security.③Experiment research,we using the serum of RA patient,testing the level of JAK-STAT proteins and some factors of NEI network,then to observe the effect of Rheumatoid one to them,in order to provide the basis of the mechanism of this drug worked on arthritis.
Methods①Theoriest part, by collectting the TCM classic theories,we found the origin theory of the knowledge "hidden-pathogens causing rheumatism doctrine".②Clinic Part:By American College Rheumatology(ACR)standard classification of2009for diagnosis basis.Ninety patients of RA were randomly divided into two group.The treatment group treated with Rheumatoid one Combined With Tripterygium wilfordii while the control group only treated withTripterygium wilfordii. The treatment of12weeks was observed in the Patients with the difference of ACR and DAS28to evaluated its clinical efficacy.Main outcome measures:include tender joint count,swellon joints count,pain joint count,visual analogue scale test,time of morning stiffness(min),hand grip strength (mmHg) and ESR,CRP,RF,a-CCP, PLT,RBC,WBC,HGB,ALT,AST.③Experiment research:we choose forty patients whose disease at the activity time, then randomly divided the forty patients into two groups as the treatment group which treated with Rheumatoid one Combined With Tripterygium wilfordii while the control group only treated with Tripterygium wilfordii. Using ELIS A method for the determination of serum JAK1,STAT3,IL-6, IL-21,SP,PRL.The observe time is twelve weeks. Meanwhile, we choose twenty healthy people as controls,. observe the change of six indexes in the serum,and compare the after-treating indexes with the before-treating in activity RA.
Results①Theoriest part, We think that main pathology mechanism of RA in periods of activity is low-speel function, damp-heat and stasis-toxicant obstructing channels and flowing to limbs joints. We work form complex way and large amount of the medicine making the drug called Rheumatoid one.②Clinic Part:after treatment for3months, the treatment group got a better overall assessment, The total effective rate of DAS28is93.3%,all patients got ACR20,77.8%patients got ACR50and42.22%patients got ACR70.Signs and symptoms aspect:Rheumatoid one play a good role not only on relieve the pain and swelling, morning stiffness, grip strength, pain VAS score and patient overall health status and also show at blood indicators:ESR, CRP, RF and a-CCP have varying degrees of decline after treatment. Meanwhile Rheumatoid one have low adverse effects, no adverse effects of combination therapy superposition.③Experiment research:the serum of JAK1,STAT3,IL-6,IL-21,SP, PRL which owed by activity RA is higher than healthy ones.After treatment,both groups make these factors low in different extent,and the group with Rheumatoid one get more obvious low in IL-6,JAK1,STAT3and SP.
Conclusion Rheumatoid one is an origin theory based on my tearchers academic thought; It can significantly alleviate the clinical symptoms of patients, significantly reduce laboratory index,and have less adverse reaction;Being activity RA,the JAK-STAT load and NEI network is being actived, Rheumatoid one can partially inhibit the activation of JAK-STAT protein and NEI network factor.
引文
[1]陈灏珠.实用内科学[M].北京：人民卫生出版社,2005：3-6
[2]蒋连泓.痹病临床经纬[M].河北：天津科学技术出版社,1993：3
[3]汪悦.风湿病中医治疗[M].南京：江苏科技出版社,2005：1-6
[4]李晶晶.越婢汤加减治疗类风湿关节炎寒热错杂证的临床研究[D].南京中医药大学,2009：3-7
[5]焦树德.类风湿关节炎从旭痹论治[J].江苏中医药,2008,40(1)：5-6
[6]张缪佳.风湿性疾病诊断流程与治疗策略[M].北京：科学出版社,2007：1-20
[7]李玲,周学平.基于数据挖掘的周仲瑛教授治疗类风湿关节炎病案回顾性研究.南京中医药大学硕士学位论文,2012,6
[8]朱良春.医学微言[M].北京：人民卫生出版社,1996：11-16.
[9]于静,金明秀.类风湿关节炎的中医病因病机探讨[J].时珍国医国药,2003,4(14)：234-235
[10]方在旺,高勇.腰肢康口服液治疗风湿性、类风湿性关节炎的临床研究[J].中外医疗,2009,(16)：97-100
[11]李晓云,张红姗,李桂等.三藤通痹丸治疗类风湿性关节炎53例临床研究[J].中国中医药信息杂志,2009,1(1)：21-24
[12]张从正.儒门事亲校注[M].郑州：河南科学技术出版社,1984：16
[13]张从正.儒门事亲校注[M].郑州：河南科学技术出版社,1984：230
[14]郑筱英.中药新药临床研究指导原则.中药新药治疗类风湿性关节炎的临床研究指导原则[s].北京：中国医药科技出版社,2002：116
[15]焦树德.再谈旭痹的辨证论治田.中医杂志,1997,(8)：504
[16]林如祥,韩渝.浅谈类风湿关节炎中医分型治疗[J].国医论坛,2007,22(1)：78
[17]付澄洲.类风湿关节炎的中医药辨治[J].内蒙古中医药,2008,(1)：20-21
[18]严余明.历节病证治浅析[J].浙江中医杂志,2008,43(6)：319-320
[19]张乃峥.临床风湿病学[M].上海：上海科学技术出版社,1999,118
[20]戴军,张玲,李孝敬.110例Epstein-Barr病毒感染及其相关疾病分析[J].基础医学与临床,2011,31(8)：932-935
[21]Altsehuler EL, Parovirus. B19 and the Pathogenesis of rheumatoid arthritis a case for historical reasoning[J].Lancet,1999,18:1026
[22]杨怡坤,胡荫奇.类风湿关节炎的发病机理探讨[J].中国骨伤,2000,13(5)：278
[23]MacGregor AJ,Snieder H, Rigby AS, et al.Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins[J].Arthritis Rheum,2000, 43:30-37
[24]Gregerson PK,Silver J,Winchester R. The shared epitope hypothesis-an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum.1987.20:1205-1213
[25]Utz PJ, Hottelet M,Sehur PH,et al. Protein phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus[J]. Exp Med,1997,185(5):834-54
[26]Murphy KM,Reiner SL. The lineage decisions of helper T cells[J]. Nat Rev Immunol,2002,2(9):33-44
[27]LATMAN NA.Relation of menstrual cycle phase to symptoms in rheumatoid arthritis[J].Am J Med,1983,74:957-960
[28]Padyukov L. Gene-gene and gene-environment interactions:what we can learn from a study of rheumatoid arthritis? Ann Rhearn Dis,2007,66 Suppl Ⅱ:48
[29]ARANEO BA,DOWEL T,DIEGUEL M, Dihydrotestosterone exerts a depressive influence on the production of IL-4,IL-5 and rIFN, but not IL-2 by activated murinecells[J].Blood,1991,78:688-699
[30]蒋明,David Yu,林孝义等.中华风湿病学[M].北京：华夏出版社,2004：188
[31]SkaPenko A,LeiPe J,LIPsky PE,et al.The role of the T cell in autoimmune Inflammation[J].Arthritis Res Ther,2005,7:4-1
[32]Panayi GS,Corrigal VM,Pitzalis C,et al.Pathogenesis of rheumatoid arthritis:The role of T cells and other beasts.Rheum Dis Clin North Am,2011,27:317-334
[33]Goldring SR.Pathogenesis of bone and cartilage destruction in rheumatoid arthritis.Rheumatology,2003,42:11-16
[34]Edwards JC,Leandro MJ,Cambridge G.B lymphocyte depletion therapy in rheumatoid arthritis [J].Rheum Dis Clin North Am,2004,30:393-403
[35]Edwards JC,Szczepanski L,Szechinski J,et al.Eficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis[J].N English Med,2004,350: 2572-2581
[36]Leandro MJ,Cooper N,Cambridge G,et al.Bone B-lineage cells in patients with rheumatoid arthritis following rituximab therapy[J].Rheumatology (Oxford),2006, 48:56-61
[37]Wong SH,Lord JM.Factors underlying chronic inflammation in rheumatoid Arthritis[J].Arch Immunol Ther EXP,2004,52:379-388
[38]Kinne RW, Brauer R,Stuhlmuller B,et al.Macrophages in rheumatoid arthritis[J]. Arthitis Res,2000,2:189-202
[39]LutZky V,Hannawi S,Thomas Rl. Cells of the synovium in rheumatoid arthritis Dendritic cells [J].Arthitis Res Ther,2007,9:219
[40]刘宁涛,杨明辉,罗文丰,等.甲氨蝶呤和雷公藤对类风湿关节炎滑膜细胞产生趋化因子的影响[J].第四军医大学学报,2006,27(12)：1113-1115
[41]Cherwinski H M,Byars N,Ballaron S J,et al.Leflunomide interferes with pyrimidine nucleotide biosynthesis[J].Inflamm Res,1995,44(8):317-322
[42]SHARP J T,STRAND V,LEUNG H,et al.Treatment with leflunomide slows radiographic progression of rheumatoid arthritis.results from three randomised controlled trims of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group [J]. Arthritis Rheum, 2010,43(3):495-505
[43]Tao X L,Lipsky P E.The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F[J]. Rheum Dis Clin North Am.2010. 1:29
[44]王胜军,姚堃,谢芳艺,等.雷公藤多甙和白细胞介素-10对人树突状细胞表面人类白细胞抗原-DR和CD80表达及白细胞介素-12 p40转录和分泌的影响[J].南京医科大学学报,2009,21(1)：1-51
[45]俞瑜,曾耀英,刘良,等.雷公藤甲素对小鼠淋巴细胞体外活化的抑制作用[J].中药材,2012,28(6)：499-502
[46]Klinkhoff A.Biological agents for rheumatoid arthritis:targeting both physical function and structural damage [J]. Drugs,2012,64 (12):1267-1283
[47]Gordon K, Korman N, Frankel E, et al Efficacy of etanercept in an integrated multistudy database of patients with p soriasis [J]. J Am Acad Dermatol,2009,54 (3 Supp 12):101-111
[48]Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe p soriasis:double-blind, randomized controlled trial and open-label extension study[J]. J Am Acad Dermatol,2011,55 (4):598-606
[49]Sag KG, Teng GG, PatkarNM, et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis[J]. Arthritis Rheum.2008,59 (6): 762-784
[50]Jiang JK, Kamran G, Francesca D, et al. Examining the chirality, conformation and selective kinase inhibition of3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo [2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550) [J]. Med Chem,2008,51(24):8012-8018
[51]Dolgin E. Companies hope for kinase inhibitor JAKpot [J]. Nat Rev Drug Discovery,2011,10(10):717-718
[52]Ottaviane E,Franchini A,Genedani S. ACTH and its immune neuroen docrine functions-Acomparative study[J].Curr pharm Des,1999,5(9):673-681
[53]张彦,宋欣伟,吴玲燕等.类风湿Ⅰ号丸对佐剂性关节炎大鼠滑膜VEGF和COX-2表达的影响[J].天津中医药,2009,26(3)：230-232
[54]戴巧定,宋欣伟,康海英等.类风湿I号丸对佐剂性关节炎大鼠镇痛作用的研究[J].中国中医药科技,2011,18(6)：476-478
[55]张卓莉.类风湿关节炎新的分类标准诞生[J].中华风湿病学杂志,2010,14(3)：212-213
[56]Fransen J,van Riel PL,The Disease Activity Score and the EULAR nesponse Criteria.Clin Exp Rheumatol,2005,23(5 suppl 39):93-99
[57]黄勇,吴敏毓.不同剂量黄芪组方的防己黄芪汤对正常小鼠免疫功能的影响[J]. 中药药理与临床,1997,13(2)：8-11
[58]孟庆常.论黄芪的双向作用[J].甘肃中医学院院报,1998,15(4)：4-5
[59]贾艳敏,陈杰.黄芪、党参、白术对脾虚大鼠脑肠轴的影响[J].实用中医内科杂志,2010,24(8)：17-18
[60]金东明,吴巍.改良半夏泻心汤治疗慢性萎缩性胃炎的实验研究[J].长春中医学院学报,2011,17(3)：41-42
[61]韩进庭.天南星药理作用与临床应用研究进展[J].现代医药卫生,2010,26(16)：2487-2488
[62]王勇,钟兵,方勇飞,等.青藤碱对类风湿关节炎患者炎性细胞因子及抗环瓜氨酸肽抗体的影响[J].第三军医大学学报,2005,27(15)：1573-157
[63]刘晓玲,陈光星,李晓娟,等.青藤碱对II型胶原诱导关节炎大鼠滑膜炎症的抑制作用及其机理探讨[J].广州中医药大学学报,2002,19(3)：214-217
[64]HuYM,LiuC,Cheng KW,et al. Sesquiterpenoids from Homalomena occulta affect osteoblast proliferation,differentiation and minerealization in vitro[J]. Phytochemistr,2008,69(12):2367-2373
[65]曾光,梁清华,刘劭,等.钻地风挥发油化学成分及抗炎活性的研究[J].天然产物研究与开发,2009,21：129-131
[66]阴健,郭力弓.中国现代研究与临床应用[M].第一册.北京：学苑出版社,1993：260
[67]张卿,高尔,侯琦,等.薤白挥发油对S180荷瘤小鼠免疫功能的影响[J].潍坊医学院学报,2008,24(2)：94-95
[68]夏怡,李祥,陈建伟,等.石膏镇痛作用的实验研究[J].中国医药导报,2009,6(9)：23-24
[69]陈晓萍,徐远扬.神经、内分泌、免疫网络的通用生物学语言[J].自然,2003,24(4)：194-197
[70]汪元,刘健,万磊,等.新风胶囊对佐剂性关节炎大鼠神经-内分泌-免疫网络相关指标的影响[J].安徽中医学报,2010,29,(2)：49-52
[71]Kremer JM, Genant HK,Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate [J]. Arthritis Rheum.2013,58 (4):953-963
[72]韩杰,刘亦青,任妍妍等.三叉神经痛大鼠脑内P物质及-β内啡肽的变化[J].山东大学学报(医学版),2013,51(8)：47
[73]康海英,宋欣伟,戴巧定.类风湿Ⅰ号对佐剂性关节炎大鼠抗炎镇痛作用的研究[J].中国中医药科技,2008,18(6)：476
[74]JORGENSEN C,BRESSOT N,BOLOGNA C.Dys-regulation of the hypohalamo-pituitary axis in rheumatoid arthritis[J].Rheumatol,1995,22:1829-1833
[75]Frey N, Grange S, Woodworth T. Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis [J].Clin Pharmacol,2010, 50(7):754-766
[76]Jones S A. Directing transition from innate to acquired immunity:defining a role for IL-6 [J]. Immunol,2012,175(6):3463-3468
[77]De Benedettif. Targeting interleukin-6 in pediatric rheumatic diseases [J]. Current opinion in rheumatology,2009,21(5):533-537
[78]Cronstein BN. Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis [J]. Bulletin of the NYU hospital for joint diseases,2007,65(1): 11-15
[79]卢建,余应年,徐仁宝主编.受体、信号转导系统与疾病[M].济南：山东科学技术出版社,2001：13-19
[80]高薇,杨娉婷,赵丽娟JAK/STAT信号转导通路与类风湿关节炎[J].中华风湿病学杂志.2006,10(9)：563-566
[81]范鸣.抗类风湿性关节炎药Tofacitinib [J].药坛快讯.2011,35(10)：480
[82]陈晓萍,徐飞JAK-STAT信号通路研究进展[J].自然杂志.2003,25(3)：149-152
[83]Kreb DL,Hilton DJ.SOCS proteins:negative regulation of cytokine signal.Stem Cells,2011,19:378-387
[1]Stark GR, Darnell JE Jr.The JAK-STAT pathway at twenty. Immunity.2012 Apr 20;36(4):503-14.
[2]Kisseleva T, Bhattacharya S, Braunstein, et al. Signal through the JAK/STAT pathway, recent advances and future challenges [J]. Gene,2002,285(1-2):1-24.
[3]Imada K, Leonard WJ. The JAK-STAT pathway [J].Mol Immunology,2000, 37(1):1-11.
[4]Parganas E, Wang D, Stravopedis D. JAK2 is essential for signaling through a variety of cytokine receptors [J].Cell,1998,93,385-595.
[5]Yamada-oka. Suita Osaka. Nuclear import and expert of proteins:the molecular basis for intracellular signaling[J]. Cytokine Growth Factor Reviews,1998,83 (4),205-221.
[6]Dan Xu, Cheng-Kui Qu. Protein tyrosine phosphates in the JAK/STAT pathway [J]. Front Biosci,2008,1,13:4925-4932.
[7]Wang rong, Cai meiying,Wu huijun, Regulation of JAK/STAT cell Factor signal pathway[J]. Progress In Microbiology and Immunology,2001,29(2):86.
[8]Malemud CJ. Intracellular Signaling Pathways in Rheumatoid Arthritis[J].J Clin Cell Immunol. 2013,19,4:160.
[9]Mertens C et al. Genes Dev [J],2006,20(24):3372-3381
[10]Schindler C. J Biol Chem,2007,282(28):20059-20063
[11]Jee SH, Chu CY, Chiu HC, et al. Interleukin-6 induced basic fibroblast growth actor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-ki-nase/Akt pathways[J]. Invest Dermatology,2004,123(6):1169-1175.
[12]Au-Yeung N, Mandhana R, Horvath CM. Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway [J]. JAKSTAT,2013,2(3):e23931.
[13]Funakoshi-Tago M et al. EMBO [J],2006,25(20):4763-4772.
[14]Gambin A, Charzynska A, Ellert-Miklaszewska A, Computational models of the JAK1/2-STAT1 signaling JAKSTAT [J].2013,2(3):e24672.
[15]Busch-Dienstfertig M, Gonzalez-Rodriguez S. IL-4, JAK-STAT signaling, and pain [J].JAKSTAT.2013, 1;2(4):e27638.
[16]Geletu M, Guy S, Arulanandam R, et al. Engaged for survival:From cadherin ligation to STAT3 activation. [J]JAKSTAT,2013,2(4):e27363.
[17]Miyamoto T.STATs and macrophage fusion [J]. JAKSTAT,2013,2(3):e24777.
[18]朱蕾.SOCS:细胞因子信号传导的负反馈抑制因子[J].国外医学：免疫学分册,2003,26(1)：1-4.
[19]Huang H, Li Y, Qi X. Cytokine signaling in the differentiation of innate effector cells [J].JAKSTAT,2013,2(1):e23531.
[20]Mahmud SA, Manlove LS, Farrar MA. Interleukin-2 and STAT5 in regulatory T cell development and function [J]. JAKSTAT,2013,2(1):e23154.
[21]Quintas-Cardama A, Verstovsek S. Molecular pathways:Jak/STAT pathway: mutations, inhibitors, and resistance[J]. Clin Cancer Res,2013,19(8):1933-1940.
[22]Kojima H, Inoue T, Kunimoto H, Nakajima K.IL-6-STAT3 signaling and premature senescence [J].JAKSTAT,2013,2(4):e25763.
[23]Hu K, Gafffen GL, Goldsmith M A. JAk/STAT signaling by cytokine receptors [J]. Curt Opin Immunol,1998,10,271-278.
[24]Cassano N, Vena GA. Janus kinase inhibition as a potential strategy for the treatment of psoriasis:state of the art and future perspectives[J]. J Biol Regul Homeost Agents,2012,26(4):587-596.
[25]高薇,杨娉婷,赵丽娟JAK/STAT信号转导通路与类风湿关节炎[J].中华风 湿病学杂志,2006,10(9)：563-566.
[26]Zheng G, Wang Y, Mahajan D, et al. The role of tubule interstitial inflammation. Kidney Int Suppl [J],2005,(94):96-100.
[27]Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and Cancer [J]. Annu Rev Immunol,2010,28:367-388.
[28]郭毅斌,陈莉萍,郑庆亦,等.抑制IL-6/STAT3信号通路对脓毒症大鼠肝损伤的影响[J],中国创伤杂志,2011,27(11)：1001-1005.
[29]Kasperkovitz P, Verbeet N, Smeets T, et al. Activation of STAT1 pathway in rheumatoid arthritis [J]. Ann Rheum Dis,2004,63:233-239.
[30]Fink K, Grandvaux N.STAT2 and IRF9:Beyond ISGF3 [J]. JAKSTAT,2013, 1,2(4):e27521.
[31]Musso T, Johnston JA, Linnekin D, et al. Regulation of JAK3 expression in human monocytes:phosphorylation in response to interleukins 2,4, and [J]. J Exp. Med,1995,181(4):1425-1431.
[32]Ihle JN. STATs:signal transducers and activators of transcription [J]. Cell,1996, 84:331-334.
[33]STAT3 regulation of and by microRNAs in development and disease. Chetram MA, Hinton CV.J Recept Signal Transduct Res.2012 Aug;32(4):190-195.
[34]范鸣.抗类风湿性关节炎药Tofacitinib [J].药学进展,2011,35(10)：480.
[2]蒋连泓.痹病临床经纬[M].河北：天津科学技术出版社,1993：3
[3]汪悦.风湿病中医治疗[M].南京：江苏科技出版社,2005：1-6
[4]李晶晶.越婢汤加减治疗类风湿关节炎寒热错杂证的临床研究[D].南京中医药大学,2009：3-7
[5]焦树德.类风湿关节炎从旭痹论治[J].江苏中医药,2008,40(1)：5-6
[6]张缪佳.风湿性疾病诊断流程与治疗策略[M].北京：科学出版社,2007：1-20
[7]李玲,周学平.基于数据挖掘的周仲瑛教授治疗类风湿关节炎病案回顾性研究.南京中医药大学硕士学位论文,2012,6
[8]朱良春.医学微言[M].北京：人民卫生出版社,1996：11-16.
[9]于静,金明秀.类风湿关节炎的中医病因病机探讨[J].时珍国医国药,2003,4(14)：234-235
[10]方在旺,高勇.腰肢康口服液治疗风湿性、类风湿性关节炎的临床研究[J].中外医疗,2009,(16)：97-100
[11]李晓云,张红姗,李桂等.三藤通痹丸治疗类风湿性关节炎53例临床研究[J].中国中医药信息杂志,2009,1(1)：21-24
[12]张从正.儒门事亲校注[M].郑州：河南科学技术出版社,1984：16
[13]张从正.儒门事亲校注[M].郑州：河南科学技术出版社,1984：230
[14]郑筱英.中药新药临床研究指导原则.中药新药治疗类风湿性关节炎的临床研究指导原则[s].北京：中国医药科技出版社,2002：116
[15]焦树德.再谈旭痹的辨证论治田.中医杂志,1997,(8)：504
[16]林如祥,韩渝.浅谈类风湿关节炎中医分型治疗[J].国医论坛,2007,22(1)：78
[17]付澄洲.类风湿关节炎的中医药辨治[J].内蒙古中医药,2008,(1)：20-21
[18]严余明.历节病证治浅析[J].浙江中医杂志,2008,43(6)：319-320
[19]张乃峥.临床风湿病学[M].上海：上海科学技术出版社,1999,118
[20]戴军,张玲,李孝敬.110例Epstein-Barr病毒感染及其相关疾病分析[J].基础医学与临床,2011,31(8)：932-935
[21]Altsehuler EL, Parovirus. B19 and the Pathogenesis of rheumatoid arthritis a case for historical reasoning[J].Lancet,1999,18:1026
[22]杨怡坤,胡荫奇.类风湿关节炎的发病机理探讨[J].中国骨伤,2000,13(5)：278
[23]MacGregor AJ,Snieder H, Rigby AS, et al.Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins[J].Arthritis Rheum,2000, 43:30-37
[24]Gregerson PK,Silver J,Winchester R. The shared epitope hypothesis-an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum.1987.20:1205-1213
[25]Utz PJ, Hottelet M,Sehur PH,et al. Protein phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus[J]. Exp Med,1997,185(5):834-54
[26]Murphy KM,Reiner SL. The lineage decisions of helper T cells[J]. Nat Rev Immunol,2002,2(9):33-44
[27]LATMAN NA.Relation of menstrual cycle phase to symptoms in rheumatoid arthritis[J].Am J Med,1983,74:957-960
[28]Padyukov L. Gene-gene and gene-environment interactions:what we can learn from a study of rheumatoid arthritis? Ann Rhearn Dis,2007,66 Suppl Ⅱ:48
[29]ARANEO BA,DOWEL T,DIEGUEL M, Dihydrotestosterone exerts a depressive influence on the production of IL-4,IL-5 and rIFN, but not IL-2 by activated murinecells[J].Blood,1991,78:688-699
[30]蒋明,David Yu,林孝义等.中华风湿病学[M].北京：华夏出版社,2004：188
[31]SkaPenko A,LeiPe J,LIPsky PE,et al.The role of the T cell in autoimmune Inflammation[J].Arthritis Res Ther,2005,7:4-1
[32]Panayi GS,Corrigal VM,Pitzalis C,et al.Pathogenesis of rheumatoid arthritis:The role of T cells and other beasts.Rheum Dis Clin North Am,2011,27:317-334
[33]Goldring SR.Pathogenesis of bone and cartilage destruction in rheumatoid arthritis.Rheumatology,2003,42:11-16
[34]Edwards JC,Leandro MJ,Cambridge G.B lymphocyte depletion therapy in rheumatoid arthritis [J].Rheum Dis Clin North Am,2004,30:393-403
[35]Edwards JC,Szczepanski L,Szechinski J,et al.Eficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis[J].N English Med,2004,350: 2572-2581
[36]Leandro MJ,Cooper N,Cambridge G,et al.Bone B-lineage cells in patients with rheumatoid arthritis following rituximab therapy[J].Rheumatology (Oxford),2006, 48:56-61
[37]Wong SH,Lord JM.Factors underlying chronic inflammation in rheumatoid Arthritis[J].Arch Immunol Ther EXP,2004,52:379-388
[38]Kinne RW, Brauer R,Stuhlmuller B,et al.Macrophages in rheumatoid arthritis[J]. Arthitis Res,2000,2:189-202
[39]LutZky V,Hannawi S,Thomas Rl. Cells of the synovium in rheumatoid arthritis Dendritic cells [J].Arthitis Res Ther,2007,9:219
[40]刘宁涛,杨明辉,罗文丰,等.甲氨蝶呤和雷公藤对类风湿关节炎滑膜细胞产生趋化因子的影响[J].第四军医大学学报,2006,27(12)：1113-1115
[41]Cherwinski H M,Byars N,Ballaron S J,et al.Leflunomide interferes with pyrimidine nucleotide biosynthesis[J].Inflamm Res,1995,44(8):317-322
[42]SHARP J T,STRAND V,LEUNG H,et al.Treatment with leflunomide slows radiographic progression of rheumatoid arthritis.results from three randomised controlled trims of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group [J]. Arthritis Rheum, 2010,43(3):495-505
[43]Tao X L,Lipsky P E.The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F[J]. Rheum Dis Clin North Am.2010. 1:29
[44]王胜军,姚堃,谢芳艺,等.雷公藤多甙和白细胞介素-10对人树突状细胞表面人类白细胞抗原-DR和CD80表达及白细胞介素-12 p40转录和分泌的影响[J].南京医科大学学报,2009,21(1)：1-51
[45]俞瑜,曾耀英,刘良,等.雷公藤甲素对小鼠淋巴细胞体外活化的抑制作用[J].中药材,2012,28(6)：499-502
[46]Klinkhoff A.Biological agents for rheumatoid arthritis:targeting both physical function and structural damage [J]. Drugs,2012,64 (12):1267-1283
[47]Gordon K, Korman N, Frankel E, et al Efficacy of etanercept in an integrated multistudy database of patients with p soriasis [J]. J Am Acad Dermatol,2009,54 (3 Supp 12):101-111
[48]Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe p soriasis:double-blind, randomized controlled trial and open-label extension study[J]. J Am Acad Dermatol,2011,55 (4):598-606
[49]Sag KG, Teng GG, PatkarNM, et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis[J]. Arthritis Rheum.2008,59 (6): 762-784
[50]Jiang JK, Kamran G, Francesca D, et al. Examining the chirality, conformation and selective kinase inhibition of3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo [2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550) [J]. Med Chem,2008,51(24):8012-8018
[51]Dolgin E. Companies hope for kinase inhibitor JAKpot [J]. Nat Rev Drug Discovery,2011,10(10):717-718
[52]Ottaviane E,Franchini A,Genedani S. ACTH and its immune neuroen docrine functions-Acomparative study[J].Curr pharm Des,1999,5(9):673-681
[53]张彦,宋欣伟,吴玲燕等.类风湿Ⅰ号丸对佐剂性关节炎大鼠滑膜VEGF和COX-2表达的影响[J].天津中医药,2009,26(3)：230-232
[54]戴巧定,宋欣伟,康海英等.类风湿I号丸对佐剂性关节炎大鼠镇痛作用的研究[J].中国中医药科技,2011,18(6)：476-478
[55]张卓莉.类风湿关节炎新的分类标准诞生[J].中华风湿病学杂志,2010,14(3)：212-213
[56]Fransen J,van Riel PL,The Disease Activity Score and the EULAR nesponse Criteria.Clin Exp Rheumatol,2005,23(5 suppl 39):93-99
[57]黄勇,吴敏毓.不同剂量黄芪组方的防己黄芪汤对正常小鼠免疫功能的影响[J]. 中药药理与临床,1997,13(2)：8-11
[58]孟庆常.论黄芪的双向作用[J].甘肃中医学院院报,1998,15(4)：4-5
[59]贾艳敏,陈杰.黄芪、党参、白术对脾虚大鼠脑肠轴的影响[J].实用中医内科杂志,2010,24(8)：17-18
[60]金东明,吴巍.改良半夏泻心汤治疗慢性萎缩性胃炎的实验研究[J].长春中医学院学报,2011,17(3)：41-42
[61]韩进庭.天南星药理作用与临床应用研究进展[J].现代医药卫生,2010,26(16)：2487-2488
[62]王勇,钟兵,方勇飞,等.青藤碱对类风湿关节炎患者炎性细胞因子及抗环瓜氨酸肽抗体的影响[J].第三军医大学学报,2005,27(15)：1573-157
[63]刘晓玲,陈光星,李晓娟,等.青藤碱对II型胶原诱导关节炎大鼠滑膜炎症的抑制作用及其机理探讨[J].广州中医药大学学报,2002,19(3)：214-217
[64]HuYM,LiuC,Cheng KW,et al. Sesquiterpenoids from Homalomena occulta affect osteoblast proliferation,differentiation and minerealization in vitro[J]. Phytochemistr,2008,69(12):2367-2373
[65]曾光,梁清华,刘劭,等.钻地风挥发油化学成分及抗炎活性的研究[J].天然产物研究与开发,2009,21：129-131
[66]阴健,郭力弓.中国现代研究与临床应用[M].第一册.北京：学苑出版社,1993：260
[67]张卿,高尔,侯琦,等.薤白挥发油对S180荷瘤小鼠免疫功能的影响[J].潍坊医学院学报,2008,24(2)：94-95
[68]夏怡,李祥,陈建伟,等.石膏镇痛作用的实验研究[J].中国医药导报,2009,6(9)：23-24
[69]陈晓萍,徐远扬.神经、内分泌、免疫网络的通用生物学语言[J].自然,2003,24(4)：194-197
[70]汪元,刘健,万磊,等.新风胶囊对佐剂性关节炎大鼠神经-内分泌-免疫网络相关指标的影响[J].安徽中医学报,2010,29,(2)：49-52
[71]Kremer JM, Genant HK,Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate [J]. Arthritis Rheum.2013,58 (4):953-963
[72]韩杰,刘亦青,任妍妍等.三叉神经痛大鼠脑内P物质及-β内啡肽的变化[J].山东大学学报(医学版),2013,51(8)：47
[73]康海英,宋欣伟,戴巧定.类风湿Ⅰ号对佐剂性关节炎大鼠抗炎镇痛作用的研究[J].中国中医药科技,2008,18(6)：476
[74]JORGENSEN C,BRESSOT N,BOLOGNA C.Dys-regulation of the hypohalamo-pituitary axis in rheumatoid arthritis[J].Rheumatol,1995,22:1829-1833
[75]Frey N, Grange S, Woodworth T. Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis [J].Clin Pharmacol,2010, 50(7):754-766
[76]Jones S A. Directing transition from innate to acquired immunity:defining a role for IL-6 [J]. Immunol,2012,175(6):3463-3468
[77]De Benedettif. Targeting interleukin-6 in pediatric rheumatic diseases [J]. Current opinion in rheumatology,2009,21(5):533-537
[78]Cronstein BN. Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis [J]. Bulletin of the NYU hospital for joint diseases,2007,65(1): 11-15
[79]卢建,余应年,徐仁宝主编.受体、信号转导系统与疾病[M].济南：山东科学技术出版社,2001：13-19
[80]高薇,杨娉婷,赵丽娟JAK/STAT信号转导通路与类风湿关节炎[J].中华风湿病学杂志.2006,10(9)：563-566
[81]范鸣.抗类风湿性关节炎药Tofacitinib [J].药坛快讯.2011,35(10)：480
[82]陈晓萍,徐飞JAK-STAT信号通路研究进展[J].自然杂志.2003,25(3)：149-152
[83]Kreb DL,Hilton DJ.SOCS proteins:negative regulation of cytokine signal.Stem Cells,2011,19:378-387
[1]Stark GR, Darnell JE Jr.The JAK-STAT pathway at twenty. Immunity.2012 Apr 20;36(4):503-14.
[2]Kisseleva T, Bhattacharya S, Braunstein, et al. Signal through the JAK/STAT pathway, recent advances and future challenges [J]. Gene,2002,285(1-2):1-24.
[3]Imada K, Leonard WJ. The JAK-STAT pathway [J].Mol Immunology,2000, 37(1):1-11.
[4]Parganas E, Wang D, Stravopedis D. JAK2 is essential for signaling through a variety of cytokine receptors [J].Cell,1998,93,385-595.
[5]Yamada-oka. Suita Osaka. Nuclear import and expert of proteins:the molecular basis for intracellular signaling[J]. Cytokine Growth Factor Reviews,1998,83 (4),205-221.
[6]Dan Xu, Cheng-Kui Qu. Protein tyrosine phosphates in the JAK/STAT pathway [J]. Front Biosci,2008,1,13:4925-4932.
[7]Wang rong, Cai meiying,Wu huijun, Regulation of JAK/STAT cell Factor signal pathway[J]. Progress In Microbiology and Immunology,2001,29(2):86.
[8]Malemud CJ. Intracellular Signaling Pathways in Rheumatoid Arthritis[J].J Clin Cell Immunol. 2013,19,4:160.
[9]Mertens C et al. Genes Dev [J],2006,20(24):3372-3381
[10]Schindler C. J Biol Chem,2007,282(28):20059-20063
[11]Jee SH, Chu CY, Chiu HC, et al. Interleukin-6 induced basic fibroblast growth actor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-ki-nase/Akt pathways[J]. Invest Dermatology,2004,123(6):1169-1175.
[12]Au-Yeung N, Mandhana R, Horvath CM. Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway [J]. JAKSTAT,2013,2(3):e23931.
[13]Funakoshi-Tago M et al. EMBO [J],2006,25(20):4763-4772.
[14]Gambin A, Charzynska A, Ellert-Miklaszewska A, Computational models of the JAK1/2-STAT1 signaling JAKSTAT [J].2013,2(3):e24672.
[15]Busch-Dienstfertig M, Gonzalez-Rodriguez S. IL-4, JAK-STAT signaling, and pain [J].JAKSTAT.2013, 1;2(4):e27638.
[16]Geletu M, Guy S, Arulanandam R, et al. Engaged for survival:From cadherin ligation to STAT3 activation. [J]JAKSTAT,2013,2(4):e27363.
[17]Miyamoto T.STATs and macrophage fusion [J]. JAKSTAT,2013,2(3):e24777.
[18]朱蕾.SOCS:细胞因子信号传导的负反馈抑制因子[J].国外医学：免疫学分册,2003,26(1)：1-4.
[19]Huang H, Li Y, Qi X. Cytokine signaling in the differentiation of innate effector cells [J].JAKSTAT,2013,2(1):e23531.
[20]Mahmud SA, Manlove LS, Farrar MA. Interleukin-2 and STAT5 in regulatory T cell development and function [J]. JAKSTAT,2013,2(1):e23154.
[21]Quintas-Cardama A, Verstovsek S. Molecular pathways:Jak/STAT pathway: mutations, inhibitors, and resistance[J]. Clin Cancer Res,2013,19(8):1933-1940.
[22]Kojima H, Inoue T, Kunimoto H, Nakajima K.IL-6-STAT3 signaling and premature senescence [J].JAKSTAT,2013,2(4):e25763.
[23]Hu K, Gafffen GL, Goldsmith M A. JAk/STAT signaling by cytokine receptors [J]. Curt Opin Immunol,1998,10,271-278.
[24]Cassano N, Vena GA. Janus kinase inhibition as a potential strategy for the treatment of psoriasis:state of the art and future perspectives[J]. J Biol Regul Homeost Agents,2012,26(4):587-596.
[25]高薇,杨娉婷,赵丽娟JAK/STAT信号转导通路与类风湿关节炎[J].中华风 湿病学杂志,2006,10(9)：563-566.
[26]Zheng G, Wang Y, Mahajan D, et al. The role of tubule interstitial inflammation. Kidney Int Suppl [J],2005,(94):96-100.
[27]Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and Cancer [J]. Annu Rev Immunol,2010,28:367-388.
[28]郭毅斌,陈莉萍,郑庆亦,等.抑制IL-6/STAT3信号通路对脓毒症大鼠肝损伤的影响[J],中国创伤杂志,2011,27(11)：1001-1005.
[29]Kasperkovitz P, Verbeet N, Smeets T, et al. Activation of STAT1 pathway in rheumatoid arthritis [J]. Ann Rheum Dis,2004,63:233-239.
[30]Fink K, Grandvaux N.STAT2 and IRF9:Beyond ISGF3 [J]. JAKSTAT,2013, 1,2(4):e27521.
[31]Musso T, Johnston JA, Linnekin D, et al. Regulation of JAK3 expression in human monocytes:phosphorylation in response to interleukins 2,4, and [J]. J Exp. Med,1995,181(4):1425-1431.
[32]Ihle JN. STATs:signal transducers and activators of transcription [J]. Cell,1996, 84:331-334.
[33]STAT3 regulation of and by microRNAs in development and disease. Chetram MA, Hinton CV.J Recept Signal Transduct Res.2012 Aug;32(4):190-195.
[34]范鸣.抗类风湿性关节炎药Tofacitinib [J].药学进展,2011,35(10)：480.